TITLE

Managing the atazanavir--tacrolimus drug interaction in a renal transplant recipient

AUTHOR(S)
Tsapepas, Demetra S.; Webber, Allison B.; Aull, Meredith J.; Figueiro, Jose M.; Saal, Stuart D.
PUB. DATE
January 2011
SOURCE
American Journal of Health-System Pharmacy;1/15/2011, Vol. 68 Issue 2, p138
SOURCE TYPE
Academic Journal
DOC. TYPE
Case Study
ABSTRACT
Purpose. The management of the drug interaction between atazanavir and tacrolimus in a renal transplant recipient is described. Summary. A 53-year-old African-American man with human immunodeficiency virus (HIV) received a renal transplant and was treated in accordance with a corticosteroidsparing immunosuppressive protocol and maintenance immunosuppression with mycophenolate mofetil and tacrolimus. His highly active antiretroviral therapy included atazanavir 400 mg daily, abacavir 600 mg daily, and lamivudine 100 mg daily. Because of the potential for a significant interaction between tacrolimus and atazanavir, the tacrolimus dosage was to be based on serum tacrolimus concentrations. The patient was initially administered one dose of tacrolimus 0.5 mg on the morning of postoperative day 2. Evaluation of the tacrolimus profiles revealed that a higher dosage was necessary because serum tacrolimus levels decreased to subtherapeutic levels by 6 hours after dose administration. In an attempt to minimize tacrolimus toxicity and limit the duration of a subtherapeutic tacrolimus level, dosing was adjusted to 1 mg every 8 hours. After 48 hours of this regimen, peak serum tacrolimus levels were lower, and the drug concentrations remained at a relatively steady level throughout the dosing interval. One final dosage adjustment (1.5 mg every 12 hours) was performed to optimize serum tacrolimus levels and patient compliance. Conclusion. In a 53-year-old man with HIV infection who underwent renal transplantation, the drug interaction between atazanavir and tacrolimus was managed by modifying the tacrolimus dosage regimen after determining the patient's blood tacrolimus concentration profile.
ACCESSION #
57414511

 

Related Articles

  • Simultaneous Islet and Kidney Transplantation in Seven Patients With Type 1 Diabetes and End-Stage Renal Disease Using a Glucocorticoid-Free Immunosuppressive Regimen With Alemtuzumab Induction. Tan, Jianming; Shunliang Yang; Jinquan Cai; Junqi Guo; Lianghu Huang; Zhixian Wu; Jin Chen; Lianming Liao // Diabetes;Oct2008, Vol. 57 Issue 10, p2666 

    OBJECTIVE--The aim of this study was to evaluate the efficiency and safety of simultaneous islet and kidney transplantation in patients with type 1 diabetes and end-stage renal disease using a glucocorticoid-free immunosuppressive regimen with alemtuzumab induction. RESEARCH DESIGN AND...

  • Transplantation: keep watching this space! Burnapp, Lisa // Journal of Renal Nursing;2011, Vol. 3 Issue 4, p160 

    The author reflects on the progress achieved on the initiatives related to transplantation in patients with end-stage kidney disease which include antibody removal programmes, paired/pooled kidney exchange scheme and non-directed altruistic donation (NDAD). She also mentions the likely benefits...

  • Costs and benefits of generic prescribing after a kidney transplant. Gupta, Gaurav; Batra, Ramesh; Alachkar, Nada // Practice Nursing;Nov2011, Vol. 22 Issue 11, p570 

    The article focuses on the use and prescription of immunosuppressant drugs after renal transplantation. It says that immunosuppressants including calcineurin inhibitors (CNIs), mycophenolate mofetil, and corticosteroids help to suppress the immune system and prevent transplant rejection. It...

  • Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease. Thariat, Juliette; Etienne-Grimaldi, Marie-Christine; Launay-Vacher, Vincent; Soto-Matos, Arturo; Fernandez-Teruel, Carlos; Ghafari, Thomas; Marcy, Pierre-Yves; Milano, Gérard; Renée, Nicole; Gastaud, Lauris; Thyss, Antoine // Cancer Chemotherapy & Pharmacology;Nov2011, Vol. 68 Issue 5, p1363 

    Purpose: The pharmacokinetics of trabectedin has never been reported in patients with impaired renal function or in patients on hemodialysis. Methods: We examined trabectedin PK in a patient on hemodialysis, starting trabectedin therapy at a standard dose for recurrence of a retroperitoneal...

  • The Experiences of Black American Living Kidney Donors.  // Nephrology Nursing Journal;Mar/Apr2011, Vol. 38 Issue 2, p193 

    No abstract available.

  • Treatment of children with chronic renal failure. Harmon, William E. // Kidney International;Mar1995, Vol. 47 Issue 3, p951 

    Reports on the treatment of children with chronic renal failure. Provision of excellent nutritional support and other conservative measures by adapting dialysis and transplant techniques; Evaluation of the relative risk of the various procedures and the effect of chronic dialysis and renal...

  • Urological consequences following renal transplantation: a review of the literature. Palazzetti, Anna; Oderda, Marco; Dalmasso, Ettore; Falcone, Marco; Bosio, Andrea; Sedigh, Omid; Frea, Bruno; Gontero, Paolo // Urologia;Oct-Dec2015, Vol. 82 Issue 4, p211 

    Renal transplant (RT) represents the treatment of choice for end-stage renal disease (ESRD) but harbours a wide range of possible complications and therapeutic challenges of urological competence. Dialysis years and clinical medical background of these patients are risk factors for sexual...

  • Single-Dose, Open-Label Study of the Differences in Pharmacokinetics of Colchicine in Subjects with Renal Impairment, Including End-Stage Renal Disease. Wason, Suman; Mount, David; Faulkner, Robert // Clinical Drug Investigation;Dec2014, Vol. 34 Issue 12, p845 

    Background and Objective: The effect of renal impairment on colchicine pharmacokinetics in patients with chronic kidney disease (CKD) has not been studied previously. We evaluated the effect of renal impairment on colchicine pharmacokinetics in patients with CKD. Methods: The pharmacokinetics...

  • Non-virological response to a dolutegravir-containing regimen in a patient harbouring a E157Q-mutated virus in the integrase region. Danion, F.; Belissa, E.; Peytavin, G.; Thierry, E.; Lanternier, F.; Scemla, A.; Lortholary, O.; Delelis, O.; Avettand-Fenoel, V.; Duvivier, C. // Journal of Antimicrobial Chemotherapy (JAC);Jun2015, Vol. 70 Issue 6, p1921 

    The article describes the case of a male patient who underwent a second kidney transplant for end-stage renal failure secondary to immunoglobulin A (IgA) nephropathy. Particular focus is given to his induction therapy and dosing regimen. Weight loss, thrush and worsening renal function are cited...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics